Dr. Dasilva examines longstanding laboratory monitoring practices in dermatology and encourages clinicians to reconsider routine testing as new evidence emerges. He reviews monitoring recommendations for therapies including interleukin (IL)-17 and IL-23 inhibitors, terbinafine, and isotretinoin, highlighting circumstances in which repeated laboratory testing may provide limited clinical benefit.
Topics Covered
- Re-evaluating routine laboratory monitoring in dermatology
- Testing considerations for IL-17 and IL-23 inhibitors
- Monitoring practices for terbinafine and isotretinoin
- Reducing unnecessary medical waste and patient anxiety
- Balancing patient safety with evidence-based care
- Adapting clinical protocols as new research becomes available
Explore Related Resources